BACKGROUND: Varicella-zoster virus (VZV) reactivation is a common complication in patients with multiple myeloma (MM) treated with bortezomib, with an incidence rate of 10%-60%. The aim of our study was to analyze the effect of acyclovir prophylaxis in this patient population. PATIENTS AND METHODS: We studied 98 consecutive patients with relapsed MM treated with bortezomib. Bortezomib 1.3 mg/m2 was given on days 1, 4, 8, and 11 of a 21-day cycle. At first, patients did not receive any VZV prophylaxis, but because of the high incidence of VZV reactivation, VZV prophylaxis with acyclovir was implemented subsequently. RESULTS: A total of 11 patients treated with bortezomib did not have any VZV prophylaxis, and 4 of these 11 patients (36%) developed VZV reactivation in the form of herpes zoster. No VZV reactivations were observed in the 32 patients who received acyclovir 400 mg 3 times daily or the 55 patients who received acyclovir in a dose reduced to 400 mg once daily during bortezomib treatment. CONCLUSION: Varicellazoster virus reactivation is a common and serious adverse effect of bortezomib treatment. Acyclovir 400 mg once daily is sufficient to protect from VZV reactivation in patients with MM treated with bortezomib.
BACKGROUND:Varicella-zoster virus (VZV) reactivation is a common complication in patients with multiple myeloma (MM) treated with bortezomib, with an incidence rate of 10%-60%. The aim of our study was to analyze the effect of acyclovir prophylaxis in this patient population. PATIENTS AND METHODS: We studied 98 consecutive patients with relapsed MM treated with bortezomib. Bortezomib 1.3 mg/m2 was given on days 1, 4, 8, and 11 of a 21-day cycle. At first, patients did not receive any VZV prophylaxis, but because of the high incidence of VZV reactivation, VZV prophylaxis with acyclovir was implemented subsequently. RESULTS: A total of 11 patients treated with bortezomib did not have any VZV prophylaxis, and 4 of these 11 patients (36%) developed VZV reactivation in the form of herpes zoster. No VZV reactivations were observed in the 32 patients who received acyclovir 400 mg 3 times daily or the 55 patients who received acyclovir in a dose reduced to 400 mg once daily during bortezomib treatment. CONCLUSION: Varicellazoster virus reactivation is a common and serious adverse effect of bortezomib treatment. Acyclovir 400 mg once daily is sufficient to protect from VZV reactivation in patients with MM treated with bortezomib.
Authors: Jonathan W Friedberg; Julie M Vose; Jennifer L Kelly; Faith Young; Steven H Bernstein; Derick Peterson; Lynn Rich; Susan Blumel; Nicole K Proia; Jane Liesveld; Richard I Fisher; James O Armitage; Steven Grant; John P Leonard Journal: Blood Date: 2011-01-14 Impact factor: 22.113
Authors: Michael Sandherr; Marcus Hentrich; Marie von Lilienfeld-Toal; Gero Massenkeil; Silke Neumann; Olaf Penack; Lena Biehl; Oliver A Cornely Journal: Ann Hematol Date: 2015-07-21 Impact factor: 3.673
Authors: Seth M Schneider; Suzanne M Pritchard; George A Wudiri; Chasity E Trammell; Anthony V Nicola Journal: mBio Date: 2019-05-14 Impact factor: 7.867
Authors: Jiri Minarik; Tomas Pika; Jakub Radocha; Alexandra Jungova; Jan Straub; Tomas Jelinek; Ludek Pour; Petr Pavlicek; Martin Mistrik; Lucie Brozova; Petra Krhovska; Katerina Machalkova; Pavel Jindra; Ivan Spicka; Hana Plonkova; Martin Stork; Jaroslav Bacovsky; Lenka Capkova; Michal Sykora; Petr Kessler; Lukas Stejskal; Adriana Heindorfer; Jana Ullrychova; Tomas Skacel; Vladimir Maisnar; Roman Hajek Journal: BMC Cancer Date: 2021-01-15 Impact factor: 4.430
Authors: Larissa Henze; Christoph Buhl; Michael Sandherr; Oliver A Cornely; Werner J Heinz; Yascha Khodamoradi; Til Ramon Kiderlen; Philipp Koehler; Alrun Seidler; Rosanne Sprute; Martin Schmidt-Hieber; Marie von Lilienfeld-Toal Journal: Ann Hematol Date: 2022-01-07 Impact factor: 3.673